

- <110> Celmed Oncology (USA), Inc. Shepard, Michael H.
- <120> Methods for treating therapy-resistant tumors
- <130> 060925-0601
- <140> US 10/048,033
- <141> 2002-11-27
- <150> PCT/US00/20007
- <151> 2000-07-21
- <150> US 60/145,364
- <151> 1999-07-22
- <150> US 60/153,855
- <151> 1999-09-14
- <160> 6
- <170> PatentIn version 3.3
- <210> 1
- <211> 19
- <212> DNA
- <213> Artificial
- <220>
- <223> Corresponding to bases 208-226 of thymidylate synthase cDNA sequence
- <400> 1

gggcagatcc aacacatcc

19

- <210> 2
- <211> 20
- <212> DNA
- <213> Artificial
- <220>
- <223> corresponding to bases 564-583

```
<400> 2
                                              20
ggtcaactcc ctgtcctgaa
<210> 3
<211> 19
<212> DNA
<213> Artificial
<220>
<223> corresponding to bases 2643-2661 of b-actin gene sequence
<400> 3
                                              19
gccaacacag tgctgtctg
<210> 4
<211> 19
<212> DNA
<213> Artificial
<220>
<223> corresponding to bases 2937-2955
<400> 4
                                             19
ctcctgcttg ctgatccac
<210> 5
<211> 26
```

cggaagettg agecgegtee geegea

<400> 5

<212> DNA <213> Artificial

<223> used for PCR amplification

<220>

<210> 6 <211> 26

<212> DNA <213> Artificial

<220>

26

<223> used for PCR amplification

<400> 6 gaaggtaccc taaacagcca tttcca

26